Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00322
|
|||||
| Drug Name |
Baricitinib
|
|||||
| Synonyms |
1187594-09-7; Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Psoriasis [ICD11: EA90] | Approved | [1] | |||
| Rheumatoid arthritis [ICD11: FA20] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H17N7O2S
|
|||||
| Canonical SMILES |
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
|
|||||
| InChI |
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
|
|||||
| InChIKey |
XUZMWHLSFXCVMG-UHFFFAOYSA-N
|
|||||
| CAS Number |
C16H17N7O2S
|
|||||
| Pharmaceutical Properties | Molecular Weight | 371.4 | Topological Polar Surface Area | 129 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
-0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103932354
, 135313591
, 136946415
, 137856279
, 144115683
, 152258684
, 160647521
, 160703522
, 162009736
, 162011992
, 162108950
, 163312339
, 164045123
, 164194014
, 170501894
, 172087008
, 172918187
, 174006690
, 174526483
, 176250838
, 185979207
, 189561494
, 198946894
, 203105586
, 208265518
, 215785530
, 223366123
, 223375538
, 223630418
, 223705259
, 224310310
, 227140190
, 244162815
, 249733389
, 249814474
, 249816401
, 252110203
, 252160600
, 252214958
, 252443897
, 252451786
, 252553656
, 85205106
, 89960290
|
|||||
| ChEBI ID |
CHEBI:95341
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Baricitinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17. | |||||
| 3 | Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.